Gerald explained how AMBS came to acquire Lympro during a conference call quite a while back. The fact that these companies had heard of the test but were wondering what happened to it is further testimony to the strength of the board and advisors for AMBS. While other companies had "heard" of it, Gerald was acquiring it for a song. Now that it has resurfaced with such an incredible team behind it should not make anyone assume it isn't a large revenue producing diagnostic test. On the contrary! The AMBS scientist and advisors saw the potential of this test. I'm sure the potential partners in this field are now up to speed as well on the potential and hopefully we will be rewarded for their foresight.